Q3 2026 NeuroOne Medical Technologies Corp Earnings Call Transcript
Key Points
- Product revenue for the 1MRF Brain Ablation System grew 16% year-over-year to $2 million, with purchase orders showing a stronger 43% growth to $2.7 million.
- Gross margins expanded significantly to 59.9% in Q3 fiscal 2026, up from 53.9% in the same quarter of the prior year, driven by a favorable product mix.
- Received ISO 13485 certification, a major milestone that paves the way for entering international markets with its 1RF brain ablation, trigeminal neuralgia, and EVO diagnostic product lines.
- A study published in the Journal of Neurosurgery by the Mayo Clinic concluded that NeuroOne's 1RF brain ablation system can be used safely in patients with existing neuromodulation implants, expanding the treatable patient pool.
- The company's STEREO CED drug delivery platform is making rapid progress, with collaborations at the University of Minnesota and Mayo Clinic, and is expected to be ready for investigational human clinical studies by the end of September.
- The lead investor increased their holdings from 7.4% to 12.5%, signaling strong confidence in the company's future prospects.
- The company has no debt outstanding as of June 30, 2026, and is working to qualify a second manufacturing site to increase capacity and reduce lead times.
- The company faces significant manufacturing and supply chain constraints, with supplier lead times of up to six months, leading to a product backlog of $1.7 million as of June 30, 2026.
- Due to manufacturing delays, the company lowered its fiscal year 2026 revenue guidance to a range of $9.2 million to $10.5 million, down from its previous expectation of at least $10.5 million, despite receiving $11.2 million in orders.
- Cash and cash equivalents decreased sharply to $2.0 million as of June 30, 2026, down from $6.6 million as of September 30, 2025, and the company has had to utilize its at-the-market (ATM) offering program to raise additional capital.
- Net loss widened in Q3 fiscal 2026 to $2.0 million, or $0.23 per basic share, compared to a net loss of $1.5 million, or $0.19 per basic share, in the same quarter of the prior year, driven by increased operating expenses.
- Total operating expenses increased to $3.6 million in Q3 fiscal 2026, up from $2.8 million in the prior year quarter, due to higher headcount and sales and marketing costs.
- The company lacks visibility into key performance indicators for its 1RF brain ablation system, as its distribution partner Zimmer Biomet does not provide detailed data on new versus existing account utilization.
- The commercialization of the trigeminal neuralgia system has been delayed as the company prioritizes manufacturing for the larger brain ablation opportunity with Zimmer Biomet, leaving the smaller product line under-supported.
Good day, ladies and gentlemen, and welcome to the EuroOne Medical Technologies Corporation's Third Quarter Fiscal 2026 Financial Results Conference Call. Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa, Chris Volker.
The company's Chief Financial Officer, and David Wambecke, the company's Chief Business Officer. Before I turn the call over to Mr. Rosa, I'd like to remind you that this conference call will include forward-looking statements within the meaning of the U.S. federal securities laws with respect to future operations, financial results, including events, trends, and performance, including our 2026 guidance. Which are based on management's beliefs and assumptions as of today's call. Forward-looking statements may involve known and unknown risks, uncertainties, and other factors, which may cause actual results to differ materially from those expressed or implied by such statements. See NeuroOne financial results press release and SEC filings for information regarding specific risks and uncertainties that could cause actual results to differ.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
